New hope for advanced cancer: first human trial of SIGX1094R begins
Disease control
Recruiting now
This early-stage study tests a new drug called SIGX1094R in about 102 adults with advanced solid tumors who have no standard treatment left. The main goals are to check the drug's safety, find the right dose, and see how it affects tumors. Researchers will also look at how food c…
Phase: PHASE1 • Sponsor: Signet Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC